European Medicines Agency loses bid to end London lease over Brexit
Reuters
Published Feb 20, 2019 05:48AM ET
European Medicines Agency loses bid to end London lease over Brexit
LONDON (Reuters) - The European Medicines Agency (EMA) has lost its bid to void a lease on its office in London's Canary Wharf financial district due to Brexit, after a judge in London on Wednesday ruled in favor of property company Canary Wharf Group.
The EMA had argued Britain's forthcoming exit from the European Union was an unexpected event that "frustrated" its 25-year lease on a building in Canary Wharf, meaning the European agency would no longer be bound to the lease.
The landmark ruling is likely to have wider implications, lawyers have said, as other tenants could have used it to try to escape from leases in Britain.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.